When.com Web Search

  1. Ads

    related to: calcitonin nasal spray prices

Search results

  1. Results From The WOW.Com Content Network
  2. Zavegepant - Wikipedia

    en.wikipedia.org/wiki/Zavegepant

    Zavegepant is a calcitonin gene-related peptide receptor antagonist. [1] It is sprayed into the nose. [1] It is sold by Pfizer. [1] The most common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting. [1] Zavegepant was approved for medical use in the United States in March 2023. [1] [2] [3] [4]

  3. Salmon calcitonin - Wikipedia

    en.wikipedia.org/wiki/Salmon_calcitonin

    Calcitonin, as salmon calcitonin (sCT), is available in the pharmaceutical market as an injectable preparation for intravenous, intramuscular or subcutaneous application. Noninvasive sCT preparation as a nasal spray is commercially produced and received US FDA approval under the proprietary name Miacalcin® in 1975 for the treatment of ...

  4. Calcitonin - Wikipedia

    en.wikipedia.org/wiki/Calcitonin

    Calcitonin is a 32 amino acid peptide hormone secreted by parafollicular cells ... In addition to the injectable and nasal spray dosage forms of the salmon calcitonin ...

  5. 6 Best Deals Coming to Costco This Spring - AOL

    www.aol.com/finance/6-best-deals-coming-costco...

    Now through April 2, Astepro's allergy steroid free antihistamine nasal spray is on sale from $10 off the regular online price of $49.99. This comes out to $13.33 per bottle for a pack of three ...

  6. FDA approves first nasal spray to treat dangerous allergic ...

    www.aol.com/lifestyle/fda-approves-first-nasal...

    ARS didn’t immediately disclose a list price, but said it would make the spray available through certain discount programs for about $200 per two-pack. Insurance plans must still decide whether ...

  7. Calcitonin gene-related peptide receptor antagonist - Wikipedia

    en.wikipedia.org/wiki/Calcitonin_gene-related...

    Zavegepant (BHV- 3500) is a nasal spray approved for acute treatment of migraines. [ 9 ] [ 10 ] Telcagepant (MK-0974), reached phase III clinical trials; development discontinued in 2011.